2023 World Conference on Lung Cancer (Posters)-P2.07. Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry

P2.07. Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry - PDF(Slides)

Pdf Summary

A retrospective study was conducted to assess the use of immune checkpoint blockers (ICBs) in patients with lung cancer who had undergone solid organ transplantation (SOT). The study aimed to evaluate the overall response rate, disease control rate, progression-free survival, overall survival, immune-related adverse events, and organ rejection rate in this patient population. <br /><br />The study included 11 patients with stage IV lung cancer who had undergone kidney transplantation. The median age of the patients was 64.8 years, with a majority being male. The most common histology was squamous cell carcinoma, and the most common metastatic sites were the liver, bone, and lung. <br /><br />All patients were receiving immunosuppressive therapy at baseline, and modifications to the therapy were made in 63% of patients before starting ICB treatment. The median follow-up time was 33.8 months. <br /><br />The overall response rate and disease control rate were 45.5% and 54.5% respectively. The median progression-free survival was 4.0 months, and the median overall survival was 4.6 months. The 6-month progression-free survival and overall survival rates were 32.7% and 42.2% respectively. The organ rejection rate was 9.1%. One patient experienced a grade 3 immune-related adverse event (colitis). <br /><br />The study concluded that ICB treatment could be a viable option for patients with metastatic lung cancer after kidney transplantation if no other treatment options are available. Collaboration with transplant experts, modification of immunosuppression, and close monitoring of this patient population are recommended strategies to minimize the risk of allograft rejection.

Asset Subtitle

Jordi Remon Masip

Meta Tag

Speaker Jordi Remon Masip

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

immune checkpoint blockers

lung cancer

solid organ transplantation

overall response rate

disease control rate

progression-free survival

overall survival

immune-related adverse events

organ rejection rate